PMID- 15671552
OWN - NLM
STAT- MEDLINE
DCOM- 20050628
LR  - 20220408
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 11
IP  - 1
DP  - 2005 Jan 1
TI  - Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal 
      squamous cell carcinoma.
PG  - 242-8
AB  - PURPOSE: To analyze the prevalence and clinical relevance of cyclin D3 
      abnormalities in laryngeal squamous cell carcinoma (LSCC). EXPERIMENTAL DESIGN: 
      Cyclin D3 immunoreactivity was evaluated in 223 formalin-fixed and 
      paraffin-embedded samples of LSCC patients with a mean follow-up of 62.8 +/- 43.2 
      months. The occurrence of cyclin D3 extra signals was analyzed by fluorescence in 
      situ hybridization in 47 randomly selected cases collected in a tissue 
      microarray. Cyclin D1 immunoreactivity had been previously investigated in 133 
      cases. RESULTS: Cyclin D3 immunoreactivity and gene extra signals were found in 
      39.5% and 42.6% of the cases, respectively, and the concordance between 
      immunohistochemical and fluorescence in situ hybridization results was 70.2% (P = 
      0.0085). Cyclin D3 immunoreactivity was significantly associated with a high risk 
      of death. Multivariate analysis showed that high tumor grade, 
      exophytic/ulcerating tumor type, low performance status, and cyclin D3 
      immunoreactivity were the only independent predictors of poor overall survival. 
      In the 133 cases analyzed for both cyclin D1 and cyclin D3, patients with cyclin 
      D1+/cyclin D3+ tumors experienced the worst prognosis, patients with cyclin 
      D1-/cyclin D3- exhibited the most prolonged survival, and with cyclin D1-/cyclin 
      D3+ or cyclin D1+/cyclin D3- tumors an intermediate course was associated. 
      CONCLUSIONS: Our data suggest that cyclin D3 immunoreactivity, possibly due to 
      the occurrence of gene extra copies, may represent an adjunct in LSCC patients' 
      prognostication and contribute to identify D-type cyclins as potential targets of 
      newly developed therapies.
FAU - Pruneri, Giancarlo
AU  - Pruneri G
AD  - Division of Pathology and Laboratory Medicine, European Institute of Oncology and 
      University of Milan School of Medicine, Milan, Italy. giancarlo.pruneri@ieo.it
FAU - Pignataro, Lorenzo
AU  - Pignataro L
FAU - Valentini, Stefano
AU  - Valentini S
FAU - Fabris, Sonia
AU  - Fabris S
FAU - Maisonneuve, Patrick
AU  - Maisonneuve P
FAU - Carboni, Nadia
AU  - Carboni N
FAU - Pece, Salvatore
AU  - Pece S
FAU - Capra, Maria
AU  - Capra M
FAU - Del Curto, Barbara
AU  - Del Curto B
FAU - Neri, Antonino
AU  - Neri A
FAU - Viale, Giuseppe
AU  - Viale G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (CCND3 protein, human)
RN  - 0 (Cyclin D3)
RN  - 0 (Cyclins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/genetics/*metabolism/*mortality
MH  - Cyclin D3
MH  - Cyclins/*biosynthesis/*genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Laryngeal Neoplasms/genetics/*metabolism/*mortality
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Oligonucleotide Array Sequence Analysis
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2005/01/27 09:00
MHDA- 2005/06/29 09:00
CRDT- 2005/01/27 09:00
PHST- 2005/01/27 09:00 [pubmed]
PHST- 2005/06/29 09:00 [medline]
PHST- 2005/01/27 09:00 [entrez]
AID - 11/1/242 [pii]
PST - ppublish
SO  - Clin Cancer Res. 2005 Jan 1;11(1):242-8.